Program, Saturday, February 27, 2021

09:00 - 09:10 Welcome & Start of the program - Jörg Beyer

09:10 - 10:30 Prostate Cancer - Chair: Thomas Hermanns, Thomas Zilli

09:10 - 09:25 Aurelius Omlin
Hot topics in prostate cancer

09:25 - 09:40 Anuradha Gopalan
Redefining high-risk prostate cancer: beyond clinical parameters

09:40 - 09:55 Ida Sonni
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold standard

09:55 - 10:10 Pirus Ghadjar
Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial

10:10 - 10:25 Mike Sathekge
Lighting the Way: Lutetium in the Treatment Paradigm

10:30 - 10:45 Break

10:45 - 11:45 Penile Cancer - Chair: Aurelius Omlin, Thomas Zilli

10:45 - 11:00 Thomas Hermanns
Overview of treatment options and controversies in penile cancer

11:00 - 11:15 Curtis Alvin Pettaway
Surgical Management of Inguinal and Pelvic Nodes in the Treatment of Penile Cancer

11:15 - 11:30 Lance C. Pagliaro
Role of Perioperative Chemotherapy in the Treatment of Penile Cancer

11:30 - 11:45 Anthony L. Zietman
Role of Chemoradiation in the Treatment of Penile Cancer: Neoadjuvant, Definitive, and Postoperative

11:45 - 12:00 Break

12:00 - 12:30 Keynote Lecture Chair: Wolfram Jochum

William G. Kaelin
The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment

12:40 - 13:30 Lunch Break
13:30 - 15:00  Kidney Cancer - Chair: Jörg Beyer, Thomas Hermanns

13:30 - 13:45  Dominik Berthold
Renal cell cancer: what are the relevant issues in 2021

13:45 - 14:00  Robert J. Motzer
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

14:00 - 14:15  Chun Loo Gan
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)

14:15 – 14:30  Sumanta K. Pal
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study

14:30 - 14:45  David Braun
Breathing new life into clear cell therapies with HIF2 therapies

14:45 - 15:00  Shankar Siva
Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial

15:00 - 15:15  Break

15:15 - 16:00  Testis Cancer - Chair: Aurelius Omlin, Thomas Hermanns

15:15 - 15:30  Jörg Beyer
Fine tuning at its best. Improving prognosis in testis cancer

15:30 - 15:45  Jonathan K. Joffe
Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST)

15:45 - 16:00  Siamak Daneshmand
SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma

16:00 - 16:15  Break

16:15 - 17:20  Bladder Cancer - Chair: Dominik Berthold, Thomas Zilli

16:15 - 16:30  Thomas Hermanns
Bladder cancer: what are the relevant issues in 2020

16:30 - 16:45  Dean F. Bajorin
First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)

16:45 - 16:55  Tracy L. Rose
Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)

16:55 - 17:05  Monika Joshi
Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival

17:05 - 17:20  Thomas Powles
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

17:20  Closing Remarks

17:30  End of program